Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
To investigate and compare the efficacy and safety of S-1 vs. Capecitabine as primary
chemotherapy in patients with inoperable or recurrent breast cancer.